BCRX (BioCryst Pharmaceuticals) PEG Ratio: N/A (As of Jun. 29, 2026)


BCRX BioCryst Pharmaceuticals Inc BCRX
64 GF Score
Price $9.56
GF Value $12.75
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BioCryst Pharmaceuticals PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, BioCryst Pharmaceuticals's PE Ratio without NRI is 0.00. BioCryst Pharmaceuticals's 5-Year EBITDA growth rate is 0.00%. Therefore, BioCryst Pharmaceuticals's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for BioCryst Pharmaceuticals's PEG Ratio or its related term are showing as below:



BCRX's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.715
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


BioCryst Pharmaceuticals  (NAS:BCRX) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


BioCryst Pharmaceuticals PEG Ratio Related Terms


BioCryst Pharmaceuticals PEG Ratio Historical Data

* Premium members only.

The historical data trend for BioCryst Pharmaceuticals's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCryst Pharmaceuticals PEG Ratio Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BioCryst Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BCRX vs SUPN, PBH, AMLX: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's PEG Ratio distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's PEG Ratio falls into.


BCRX
64GF Score
BioCryst Pharmaceuticals Inc BCRX
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCryst Pharmaceuticals PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

BioCryst Pharmaceuticals's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of $9.56 is trading 25% below its estimated GF Value™ of $12.75. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for BCRX:

  • PEG Ratio: N/A
  • GF Value™: $12.75 vs. price of $9.56 (25% below fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioCryst Pharmaceuticals Business Description

Other Exchanges BCRX:MexicoBO1:Germany
Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
64GF Score

Get the complete analysis for BCRX

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.56
Price
$12.75
GF Value